Ionis Pharmaceuticals IONS Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's deferred revenue?
- Ionis Pharmaceuticals (IONS) reported deferred revenue of $69.2M in Q1 2026.
- How has Ionis Pharmaceuticals's deferred revenue changed year-over-year?
- Ionis Pharmaceuticals's deferred revenue decreased by 14.7% year-over-year, from $81.1M to $69.2M.
- What is the long-term trend for Ionis Pharmaceuticals's deferred revenue?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's deferred revenue has grown at a -7.4% compound annual growth rate (CAGR), from $108.38M to $73.76M.
- What does deferred revenue mean?
- Money received in advance for products or services that the company has not yet provided.
- How do you interpret deferred revenue?
- An increase typically signals strong future revenue recognition potential from existing partnerships, while a decrease may indicate the fulfillment of contractual obligations.
- How does deferred revenue compare across companies?
- Common in companies with heavy R&D collaboration models and milestone-based revenue structures.